{'fraction_non_alphanumeric': 0.02843601895734597, 'fraction_numerical': 0.006635071090047393, 'mean_word_length': 5.559006211180124, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The effects of terazosin hydrochloride and buflomedil in patients with hemicrania without aura].

Considering the pharmacologic properties of terazosine and buflomedil, the authors postulated a prophylactic activity of these drugs for paroxysmal headache in migraine patients without aura. Therefore, in an open trial, 46 such patients were subdivided into three groups, the first of which (10 patients) was treated with terazosine, the second (29 patients) with buflomedil, and the third (7 patients) with both drugs according to a previously elaborated protocol with periodical assessment of the M.I.C. (Migraine Index Corrected). At the end of the treatment period, statistically evaluated M.I.C. variations appeared to indicate that buflomedil had better therapeutic activity than terazosine and the terazosine-buflomedicl combination. Finally, the authors discuss some hypotheses in the attempt to account for the mechanism of action since the lesser therapeutic effect of the combination compared to buflomedil alone cannot be reasonably explained.